SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria
In this meta-analysis, SGLT2 inhibitors were found to lower the risk of CKD progression regardless of baseline eGFR or albuminuria, including in patients with stage 4 CKD or minimal albuminuria, supporting their routine use to improve kidney outcomes across the full spectrum of kidney function among patients with type 2 diabetes, CKD, or heart failure.
Authors
- Stefan D. Anker (ORCID: https://orcid.org/0000-0002-0805-8683)
- Silvio E. Inzucchi
- Milton Packer
- Kieran F. Docherty (ORCID: https://orcid.org/0000-0002-5446-9969)
- Deepak L. Bhatt (ORCID: https://orcid.org/0000-0002-1278-6245)
- Adrian F. Hernandez (ORCID: https://orcid.org/0000-0003-3387-9616)
- Brendon Lange Neuen (ORCID: https://orcid.org/0000-0001-9276-8380)
- Robert A. Fletcher (ORCID: https://orcid.org/0000-0002-0885-1788)
- Javed Butler (ORCID: https://orcid.org/0000-0001-7683-4720)
- Finnian R. Mc Causland (ORCID: https://orcid.org/0000-0002-0299-0533)
- John J.V. McMurray (ORCID: https://orcid.org/0000-0002-6317-3975)
- Vlado Perkovic (ORCID: https://orcid.org/0000-0002-4257-7620)
- Natalie Staplin (ORCID: https://orcid.org/0000-0003-4482-4418)
- David Z.I. Cherney (ORCID: https://orcid.org/0000-0003-4164-0429)
- Marc S. Sabatine (ORCID: https://orcid.org/0000-0002-0691-3359)
- Hiddo J.L. Heerspink (ORCID: https://orcid.org/0000-0002-3126-3730)
- Kenneth W. Mahaffey (ORCID: https://orcid.org/0000-0002-3791-2148)
- Siddharth M. Patel (ORCID: https://orcid.org/0000-0002-4637-4361)
- Muthiah Vaduganathan (ORCID: https://orcid.org/0000-0003-0885-1953)
- David Collins. Wheeler (ORCID: https://orcid.org/0000-0003-0745-3478)
- Darren K. McGuire (ORCID: https://orcid.org/0000-0002-6412-7989)
- Bruce Charles Neal (ORCID: https://orcid.org/0000-0002-0490-7465)
- William Guy Herrington (ORCID: https://orcid.org/0000-0003-1172-8243)
- Richard Haynes (ORCID: https://orcid.org/0000-0002-1179-0023)
- Stefan D. Anker (ORCID: https://orcid.org/0000-0003-3331-7314)
- Hiddo JL Heerspink
- Meg Jardine (ORCID: https://orcid.org/0000-0002-0160-2375)
- Vlado Perkovic
- Scott D Solomon
- Scott Solomon
- Muthiah Vaduganathan
- Christoph Wanner
- Faïez Zannad
- Faiez Zannad
- C. Wanner
- Rebecca J. Sardell
- Stefan James
Institutions
- Brigham and Women's Hospital (US)
- The University of Sydney (AU)
- University Health Network (CA)
- University Medical Center Groningen (NL)
- Harvard University (US)
- Inserm (FR)
- University of Toronto (CA)
- Royal North Shore Hospital (AU)
- Baylor University Medical Center (US)
- Council for British Research in the Levant (GB)
- UNSW Sydney (AU)
- British Heart Foundation (GB)
- Yale University (US)
- University of Oxford (GB)
- Baylor Scott & White Medical Center - Temple (US)
- Smart Material (Germany) (DE)
- The George Institute for Global Health (AU)
- Universitätsklinikum Würzburg (DE)
- German Centre for Cardiovascular Research (DE)
- Oxford University Hospitals NHS Trust (GB)
- Center for Clinical Research (United States) (US)
- Thrombolysis in Myocardial Infarction Study Group (US)
- National Health and Medical Research Council (AU)
- University College London (GB)
- Imperial College London (GB)
- Charité - Universitätsmedizin Berlin (DE)
- University of Glasgow (GB)
- The University of Texas Southwestern Medical Center (US)
- Université de Lorraine (FR)
- Stanford University (US)
Publication Details
- Journal
- JAMA
- Published
- 2025-11-08
- DOI
- https://doi.org/10.1001/jama.2025.20834
- Citations
- 12
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 17.17